MetaCap

Celularity (CELU) vs Shuttle Pharmaceuticals (SHPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Celularity (CELU) has outperformed Shuttle Pharmaceuticals (SHPH) over the past year, losing 73.5% versus a loss of 78.2%. Shuttle Pharmaceuticals is the larger company by market cap ($16.6 million vs $15.0 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CELU-73.54%SHPH-78.19%
+63%-13%-90%
Nov 21, 20251 yearNov 20, 2026
CELU-98.32%SHPH-99.99%
+173%+30%-113%
Aug 29, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CELU versus SHPH key metrics
MetricCELUSHPH
Share price$0.463$3.49
Market cap$15.02M$16.63M
1-day change-1.05%-10.51%
YTD return-58.29%-80.61%
1-year return-73.54%-78.19%
5-year return-99.31%—
EPS (TTM)$-1.69$-16.87
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$26.55M—
Revenue growth (YoY)-51.03%—
Net income (latest FY)$-91.72M$-11.72M
Gross margin24.39%—
Operating margin-230.92%—
Net margin-345.45%—
52-week high$2.55$44.40
52-week low$0.42$2.58
Distance from 52-week high-81.84%-92.14%
Average volume3.95M41.80K
Shares outstanding32.45M4.76M
Employees1152
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Celularity

CELU stock →

Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking.

Health Care · Biotechnology: Pharmaceutical Preparations · 115 employees

About Shuttle Pharmaceuticals

SHPH stock →

Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development.

Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees

CELU vs SHPH FAQ

Which is bigger, Celularity or Shuttle Pharmaceuticals?

Shuttle Pharmaceuticals (SHPH) is larger, with a market capitalization of $16.63M compared with $15.02M for Celularity (CELU).

Which stock has performed better over the past year, CELU or SHPH?

CELU returned -73.54% over the past 12 months, compared with -78.19% for SHPH (price return, excluding dividends). Past performance does not predict future results.

Are Celularity and Shuttle Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons